DLH Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Q2 FY2026 revenue declined year-over-year due to contract transitions, but adjusted EBITDA margin remained strong at 9%. Debt reduction efforts are ahead of schedule, and a key NIH contract extension boosts revenue visibility. Several large bids are pending decisions.
-
The meeting approved all proposals, including director elections, executive compensation, equity plan amendment, and auditor ratification. Strategic updates highlighted ongoing AI-driven transformation, cost savings, and a strong contract pipeline, with management addressing shareholder questions on operations and growth.
-
Q1 revenue and EBITDA declined year-over-year due to program transitions, but sequential margins improved and free cash flow usage decreased. Budget clarity and increased federal funding support a positive outlook, with cost reductions and debt deleveraging on track.
Fiscal Year 2025
-
Fiscal 2025 saw lower revenue and EBITDA due to contract transitions and policy changes, but strong cash flow enabled significant debt reduction. With a robust $3B+ pipeline and new technology-driven offerings, expectations are high for growth and margin recovery in fiscal 2026.
-
Q3 2025 revenue fell to $83.3M from $100.7M year-over-year, mainly due to contract transitions and government efficiency initiatives. EBITDA was $8.1M, with strong cash flow supporting aggressive debt reduction. Management remains optimistic about growth as federal priorities shift toward technology and procurement reforms.
-
Q2 FY25 revenue declined year-over-year due to contract set-asides, but EBITDA margin improved and strong cash flow enabled significant debt reduction. The business pipeline is robust, with major contract awards expected in the second half, and the company remains well-positioned for growth.
-
Revenue and EBITDA declined year-over-year due to small business set-aside conversions and contract timing, but a strong pipeline and recent contract wins are expected to drive future growth. Debt reduction remains a priority, with over half of EBITDA targeted for deleveraging.
Fiscal Year 2024
-
Fiscal 2024 saw record revenue and strong EBITDA, with a $76 million Navy contract win and a robust $4 billion pipeline positioning for future growth. Headwinds from small business set-asides and procurement delays are being managed with strategic investments and debt reduction.
-
Q3 revenue was $100.7M with EBITDA of $10M, impacted by small business set-aside transitions, but core markets grew year-over-year. Management expects new contract wins to drive growth and is focused on debt reduction, despite ongoing risks from government procurement changes.